GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vectus Biosystems Ltd (ASX:VBS) » Definitions » EPS without NRI

Vectus Biosystems (ASX:VBS) EPS without NRI : A$-0.04 (TTM As of Dec. 2023)


View and export this data going back to 2016. Start your Free Trial

What is Vectus Biosystems EPS without NRI?

Vectus Biosystems's earnings per share without non-recurring items for the six months ended in Dec. 2023 was A$-0.02. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.04.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 17.20% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 0.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Vectus Biosystems's EPS without NRI or its related term are showing as below:

ASX:VBS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -20.8   Med: 7.8   Max: 25
Current: 17.2

During the past 8 years, Vectus Biosystems's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 25.00% per year. The lowest was -20.80% per year. And the median was 7.80% per year.

ASX:VBS's 3-Year EPS without NRI Growth Rate is ranked better than
65.15% of 1274 companies
in the Biotechnology industry
Industry Median: 4.85 vs ASX:VBS: 17.20

Vectus Biosystems's EPS (Diluted) for the six months ended in Dec. 2023 was A$-0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.04.

Vectus Biosystems's EPS (Basic) for the six months ended in Dec. 2023 was A$-0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.04.


Vectus Biosystems EPS without NRI Historical Data

The historical data trend for Vectus Biosystems's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vectus Biosystems EPS without NRI Chart

Vectus Biosystems Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EPS without NRI
Get a 7-Day Free Trial -0.07 -0.13 -0.15 -0.12 -0.07

Vectus Biosystems Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 -0.04 -0.05 -0.02 -0.02

Competitive Comparison of Vectus Biosystems's EPS without NRI

For the Biotechnology subindustry, Vectus Biosystems's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vectus Biosystems's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vectus Biosystems's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Vectus Biosystems's PE Ratio without NRI falls into.



Vectus Biosystems EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vectus Biosystems  (ASX:VBS) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Vectus Biosystems EPS without NRI Related Terms

Thank you for viewing the detailed overview of Vectus Biosystems's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Vectus Biosystems (ASX:VBS) Business Description

Traded in Other Exchanges
N/A
Address
3-11 Primrose Avenue, Rosebery, Sydney, NSW, AUS, 2018
Vectus Biosystems Ltd is an emerging biotechnology company based in Sydney, Australia. The company is in the process of developing a treatment for fibrosis and high blood pressure, which includes heart, kidney, and liver diseases. The company has also developed a technology aimed at improving the speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories.

Vectus Biosystems (ASX:VBS) Headlines

No Headlines